Utama › Kanser Payudara Triple-Negatif › California › San Francisco
Kajian klinikal Kanser Payudara Triple-Negatif di San Francisco, CA
11 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi dalam dan sekitar San Francisco (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Mengambil pesertaFasa 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Mengambil pesertaFasa 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Mengambil pesertaFasa 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Mengambil pesertaFasa 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Mengambil pesertaFasa 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Mengambil pesertaFasa 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Mengambil pesertaFasa 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
Mengambil pesertaKajian pemerhatian
- Curebase, San Francisco
Kajian Kanser Payudara Triple-Negatif di bandar lain
- Houston, TX42 kajian
- New York City, NY31 kajian
- Nashville, TN28 kajian
- Los Angeles, CA27 kajian
- Boston, MA26 kajian
- San Antonio, TX23 kajian
- St. Louis, MO21 kajian
- Arlington, VA20 kajian
- Atlanta, GA20 kajian
- Dallas, TX18 kajian
- Chicago, IL16 kajian
- Columbus, OH16 kajian
Kajian lain di San Francisco
- Kanser Prostat45 kajian
- Kanser Payudara43 kajian
- Kanser Paru-paru Bukan Sel Kecil36 kajian
- Kanser (semua jenis)35 kajian
- Kegagalan Jantung29 kajian
- Kanser Metastatik28 kajian
- Kanser Paru-paru22 kajian
- Melanoma22 kajian
- Kanser Pankreas20 kajian
- Kanser Ovari19 kajian
- Kanser Kolorektal18 kajian
- Penyakit Kardiovaskular18 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.